The first real-world study of the FDA-approved non-hormone treatment fezolinetant found the menopausal medication improved hot flashes, depression and anxiety in women, according to industry-sponsored research being presented Sunday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, Ill.